Geographic Atrophy Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Geographic Atrophy Pipeline Insight 2024" report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Geographic Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Geographic Atrophy Research. Learn more about our innovative pipeline today! @ Geographic Atrophy Pipeline Outlook- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Geographic Atrophy Pipeline Report
• In November 2024:- Alexion Pharmaceuticals Inc.- This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.
• In November 2024:- Annexon Inc.- A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD). The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
• In November 2024:- Genentech Inc.- A Phase IIa, Multicenter, Open-Label, Single-Arm Study To Optimize Subretinal Surgical Delivery And To Evaluate Safety And Activity Of Opregen In Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration. This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.
• DelveInsight's Geographic Atrophy pipeline report depicts a robust space with 23+ active players working to develop 25+ pipeline therapies for Geographic Atrophy treatment.
• The leading Geographic Atrophy Companies such as Complement Therapeutics, Aevitas Therapeutics, Nanoscope Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, Genentech, Apellis Pharmaceuticals, Pegol Iveric Bio, and others.
• Promising Geographic Atrophy Therapies such as CTx001, AAV.sFH, MCO 020, ONL 1204, RO7303359, NGM621, ANX 007, OpRegen, Pegcetacoplan, Avacincaptad, and others.

Stay informed about the cutting-edge advancements in Geographic Atrophy treatments. Download for updates and be a part of the revolution in care @ Geographic Atrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Geographic Atrophy Emerging Drugs Profile

• IONIS-FB-LRx: Ionis Pharmaceuticals
IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye.

• Zimura: IVERIC bio
Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. This potential mechanism is the rationale for Zimura as a potential therapy for geographic atrophy secondary to age-related macular degeneration.

Learn more about Geographic Atrophy Drugs opportunities in our groundbreaking Geographic Atrophy Research and development projects @ Geographic Atrophy Unmet Needs- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Geographic Atrophy Companies
Complement Therapeutics, Aevitas Therapeutics, Nanoscope Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, Genentech, Apellis Pharmaceuticals, Pegol Iveric Bio, and others.

Geographic Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.

Geographic Atrophy Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Geographic Atrophy treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Geographic Atrophy Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Geographic Atrophy Pipeline Report
• Coverage- Global
• Geographic Atrophy Companies- Complement Therapeutics, Aevitas Therapeutics, Nanoscope Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, Genentech, Apellis Pharmaceuticals, Pegol Iveric Bio, and others.
• Geographic Atrophy Therapies- CTx001, AAV.sFH, MCO 020, ONL 1204, RO7303359, NGM621, ANX 007, OpRegen, Pegcetacoplan, Avacincaptad, and others.
• Geographic Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Geographic Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Geographic Atrophy Pipeline on our website @ Geographic Atrophy Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Geographic Atrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Geographic Atrophy - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Zimura: IVERIC bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IONIS-FB-LRx: Ionis Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Geographic Atrophy Key Companies
15. Geographic Atrophy Key Products
16. Geographic Atrophy- Unmet Needs
17. Geographic Atrophy- Market Drivers and Barriers
18. Geographic Atrophy- Future Perspectives and Conclusion
19. Geographic Atrophy Analyst Views
20. Geographic Atrophy Key Companies
21. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.